Lundbeck to buy U.S. firm Chelsea Therapeutics for up to $658 mln

COPENHAGEN, May 8 (Reuters) 

Danish pharmaceutical company H. Lundbeck is to buy Chelsea Therapeutics for up to $658 million in a deal that would give it the rights to the U.S firm's neurology drug Northera.

Chelsea stockholders will be offered $6.44 per share in cash and contingent value rights (CVRs) that may pay up to $1.50 per share, the two firms said. The total would represent a premium of 59 percent over Wednesday's closing price of Chelsea shares.

By acquiring Chelsea Therapeutics, Lundbeck would gain the rights to Northera, which was recently approved by the U.S. Food and Drug Administration and is expected to be launched in the third quarter of 2014.

The drug treats a rare form of low blood pressure associated with neurological disorders such as Parkinson's disease.

Northera has the potential to become the most valuable of Lundbeck's four neurological drugs in the United States, the Danish company said.

Lundbeck Chief Executive Ulf Wiinberg said at a conference call that the drug "fits perfectly" into Lundbeck's existing portfolio of drugs, which mainly consists of drugs for brain diseases.

The Chelsea board unanimously approved the transaction but it still requires the approval of Chelsea shareholders which Lundbeck said it expected to receive in the summer.

"Lundbeck is doing this to increase its long-term earnings," Sydbank analyst Soren Lontoft Hansen told Reuters. "The criteria for success is whether they can generate a peak (annual) sale for Northera of $400 million."

Shares in Lundbeck were up 0.4 percent at 1325 GMT, outperforming the Danish benchmark index which was down 0.1 percent. Shares in Chelsea Therapeutics were up 32.8 percent in premarket trading.

 “Pharmaceutical Marketing for Non – Marketers” 

30 - 31 of May - Metropolitan Hotel, Athen


Click here to download the seminar brochure: 

https://www.dropbox.com/s/ua7bfnkh4c9bmg3/Pharma%20Marketing%20for%20Non%20Marketers.pdf
  

Payers don't trust pharma. The fix? Risky trials and transparency

New survey research finds that the majority payers in the US and Europe believe that drug adherence solutions and data that pharma companies possess are vital to lowering health care costs and improving outcomes. However, lingering mistrust of the pharma industry is likely to stymie efforts by pharma companies to engage with payers in these areas without a fundamental change from current approaches. These and other findings were released today in Progressions: Navigating the payer landscape, Ernst & Young 's annual report on the global pharmaceutical industry.

As part of this year's Progressions report, Ernst & Young surveyed 30 US payers and 30 European payers on their current and future needs and preferences, and 18 global pharmaceutical companies on how well they understand payers' needs and attitudes. This survey was supplemented by in-depth interviews with industry executives in the US and Europe. Key findings include:

Τα απαγορευμένα σποτάκια και η ανακοίνωση του Φαρμακευτικού Συλλόγου Αττικής

AΘΗΝΑ   6  ΜΑΪΟΥ   2014        

                                                                  ΠΡΟΣ

                       

-      Μ.Μ.Ε.

-      ΟΛΑ ΤΑ ΚΟΜΜΑΤΑ

ΔΕΛΤΙΟ ΤΥΠΟΥ

«ΦΙΜΩΣΗ ΤΗΣ ΔΗΜΟΚΡΑΤΙΑΣ»

Η κυβέρνηση προχώρησε σήμερα, σε μία πρωτοφανή πράξη φίμωσης του Δημοκρατικού λόγου, και της ελεύθερης έκφρασης πολιτικών φορέων, συνδικαλιστικών οργανώσεων επιστημονικών κλάδων κ.λ.π.

Απαγορεύει με Υπουργική Απόφαση την μετάδοση οποιουδήποτε μηνύματος μπορεί να χαρακτηριστεί από την κυβέρνηση ως πολιτικό και που προφανώς «θα την βλάψει» ενόψει των επερχόμενων εκλογών.

Αυτή η πρωτοφανής λογοκρισία δεν έχει προηγούμενο σε μία ευνομούμενη Δημοκρατία.

Ο ΦΣΑ καλεί όλα τα κόμματα να πάρουν θέση. Δηλώνει προς κάθε κατεύθυνση ότι με αυτές τις ενέργειες οι φαρμακοποιοί πεισμώνουν ακόμη περισσότερο και θα δυναμώσουν τους αγώνες τους.  Να είναι σίγουροι οι εμπνευστές – λογοκριτές ότι οι φαρμακοποιοί θα καταδικάσουν και με την ψήφο τους, αυτούς που τα τελευταία χρόνια έχουν οδηγήσει ολόκληρη την κοινωνία σε ανθρωπιστική κρίση.

ΓΙΑ ΤΟΝ Φ.Σ.Α.

Ο   ΠΡΟΕΔΡΟΣ                                                 Ο ΓΡΑΜΜΑΤΕΑΣ

ΚΩΝΣΤΑΝΤΙΝΟΣ  ΛΟΥΡΑΝΤΟΣ                      ΗΛΙΑΣ  ΓΙΑΝΝΟΓΛΟΥ


Δείτε εδώ τα απαγορευμένα σποτάκια

https://www.youtube.com/watch?v=jQ07s3E1WFE&feature=youtu.be

https://www.youtube.com/watch?v=7Q_5iuS27DE&feature=youtu.be

 

Three days left to get registered at the early bird rate to attend the “Pharmaceutical Marketing for Non – Marketers” seminar.

30 - 31 of May - Metropolitan Hotel, Athens

Early Bird Registrations until, Friday 9th May. 


Click here to download the seminar brochure: 

https://www.dropbox.com/s/ua7bfnkh4c9bmg3/Pharma%20Marketing%20for%20Non%20Marketers.pdf
  

Novartis and GSK’s multi-billion dollar swaps to transform both companies

Novartis has unveiled a dazzling multi-billion dollar business deal which sees it divest its vaccines and animal health divisions, build its oncology portfolio, and create a new joint venture market leader in OTC medicines. The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 billion dependent on milestones.

The deal will not only transform Novartis, but GSK as well, with both companies clearly focusing on strategies to make them true market leaders in their chosen areas. The underlying thinking for both firms is to exit therapy areas where they are an 'also ran' and create critical mass in key areas.

Three days left to get registered at the early bird rate to attend the “Pharmaceutical Marketing for Non – Marketers” seminar.

30 - 31 of May - Metropolitan Hotel, Athens

Early Bird Registrations until, Friday 9th May.

Click here to download the seminar brochure: 

https://www.dropbox.com/s/ua7bfnkh4c9bmg3/Pharma%20Marketing%20for%20Non%20Marketers.pdf

The deal also see Novartis divest its animal health division to Lilly for around $5.4 billion.

Creating market leading franchises

For Novartis, oncology is a key strategic area, but it is still short of dominating the field.

Bayer aims to crush consumer health rivals with $14B Merck unit buyout

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion). "This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," explained Bayer CEO Dr. Marijn Dekkers. "At the same time we are leveraging our capabilities in the cardiovascular therapeutic area." In a related transaction, Bayer has entered into a global co-development and co-commercialization agreement with Merck & Co., Inc. in the field of soluble guanylate cyclase (sGC) modulators, for which Merck & Co., Inc. will make an up-front payment to Bayer of USD 1 billion, with substantial additional sales milestone payments.

Significant enhancement of Bayer's consumer care business

The acquisition will give Bayer the global number two position in non-prescription (over-the-counter, OTC) products following recently announced consolidations in this highly attractive and growing healthcare industry segment, and will significantly enhance Bayer's business across multiple therapeutic categories and geographies. Merck & Co., Inc.'s consumer care business includes leading brands such as Claritin™, Coppertone™ and Dr. Scholl's™.

Are pharmaceutical mega-mergers in the public interest?

Guardian | Barbara Arzymanow   

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D - with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played a central role in the development of almost all medicines available today. The industry has made a major contribution to the health and life expectancy of the world’s population.

Apart from encouraging R&D the most important reasons to support the pharmaceutical industry are economic: to create highly skilled jobs and in the case of individual countries to promote exports. Finally, there is a benefit to the advancement of science, which many economists, pure scientists and academics would see as an end in itself.

The two key questions relevant to any major pharmaceutical company merger are:

Big Pharma stands to profit by cleaning out its medicine chests

Reuters | By Ransdell Pierson

Leading global pharmaceutical companies have started to view their vast portfolios of older, established prescription drugs as vehicles for raising large sums of cash to fuel development of new medicines with far higher profit margins.

France's Sanofi and U.S. drugmakers Merck & Co and Abbott Laboratories are exploring selling off their mature drugs that have lost patent protection, Reuters reported this week, citing people familiar with the plans. Officials at the three companies declined to comment.

The divestments could bring in more than $7 billion for Sanofi, north of $15 billion for Merck and over $5 billion for Abbott, the sources said, giving them considerable firepower to develop, or buy, promising experimental medicines.

Next deal up for Merck: Selling $15 billion worth of older brands

Merck & Co Inc is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.

Merck, which is also in the process of selling its $14 billion consumer healthcare unit, is working with an investment bank on the potential sale of the off-patent drugs, which could draw interest from generic drugmakers, the people said.

Merck's off-patent drugs are called "diversified brands" and many are sold in emerging markets.

UK lawmakers plan to probe Pfizer pursuit of AstraZeneca

Reuters | By Kylie MacLellan and Ben Hirschler

British lawmakers intend to investigate U.S. drugmaker Pfizer's planned $100 billion takeover of British rival AstraZeneca in a bid to ensure scientific research and jobs are protected.

Members of the parliamentary business, innovation and skills committee are worried that the deal, which would be the biggest-ever foreign acquisition of a British company, could threaten the country's strategic interests.

"We are keen to look closely at it," committee member Ann McKechin told Reuters.

Amazing Seminar for Pharmaceutical Executives

Για να κατεβάσετε το αναλυτικό έντυπο από τον υπολογιστή σας πατήστε εδώ.

Για να κατεβάσετε το αναλυτικό έντυπο από το tablet ή το τηλέφωνο σας πατήστε εδώ